Brief: Merck Strengthens Immunology Pipeline With Acquisition Of Prometheus Biosciences Inc

Prometheus Biosciences

16/04/2023 11:07

April 16 (Reuters) - Merck & Co Inc  MRK.N :
    * MERCK STRENGTHENS IMMUNOLOGY PIPELINE WITH ACQUISITION OF
PROMETHEUS BIOSCIENCES, INC.
    * MERCK- MERCK, THROUGH A SUBSIDIARY, HAS AGREED TO ACQUIRE
PROMETHEUS FOR $200.00 PER SHARE IN CASH FOR A TOTAL EQUITY
VALUE OF APPROXIMATELY $10.8 BILLION.
    * MERCK- TRANSACTION IS EXPECTED TO CLOSE IN Q3 OF 2023.
    * MERCK- MERCK, THROUGH A SUBSIDIARY, WILL ACQUIRE ALL OF
OUTSTANDING SHARES OF PROMETHEUS

Source text for Eikon:  ID:nBw6cPKyga 
Further company coverage:  MRK.N 

 ((Reuters.Briefs@thomsonreuters.com;))